Carlo Toniatti - Concepedia

Author

Carlo Toniatti

IRBM Science Park ORCID

Also Known As

C TONIATTI, C Toniatti, C. TONIATTI, C. Toniatti, CARLO TONIATTI, Carlo Toniatti, Toniatti, C, Toniatti, Carlo

211

Publications

10.2K

Citations

H-Index

104

Concepts

All Affiliations

IRBM Science Park The University of Texas MD Anderson Cancer Center Institute of Molecular Biology and Pathology Merck & Co., Inc., Rahway, NJ, USA (United States)Istituto di Genetica Molecolare

About

Carlo Toniatti is an author at IRBM Science Park specializing in medicine, cell biology, and immunology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	30	44	6.4K
2	Natural Sciences	12	12	744
3	Engineering	2	2	38
4	Social Sciences	1	1	21
5	Allergy	1	1	53

Carlo Toniatti

Publications

10K

Citations

H-Index

Page 1

	Year	Citations
Role of IL-6 and Its Soluble Receptor in Induction of Chemokines and Leukocyte Recruitment Maria Romano, Marina Sironi, Carlo Toniatti, Immunity InflammationCytokineChemokine BiologyAutoimmune DiseaseImmune Regulation	1997	1.1K
An inhibitor of oxidative phosphorylation exploits cancer vulnerability Jennifer R. Molina, Yuting Sun, Marina Protopopova, Nature Medicine MedicineAnti-cancer AgentCancer VulnerabilityPharmacologyTumor Microenvironment	2018	903
Co-occurring Genomic Alterations Define Major Subsets of <i>KRAS</i> -Mutant Lung Adenocarcinoma with Distinct Biology, Immune Profiles, and Therapeutic Vulnerabilities Ferdinandos Skoulidis, Lauren A. Byers, Lixia Diao, Cancer Discovery	2015	883
The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial Shahneen Sandhu, William R. Schelman, George Wilding, The Lancet Oncology Sporadic CancerMedicineBrca Mutation CarriersPathologyCancer Treatment	2013	551
Interleukin (IL)-6 gene expression in the central nervous system is necessary for fever response to lipopolysaccharide or IL-1 beta: a study on IL-6-deficient mice. Zhen Chai, S. Gatti, Carlo Toniatti, The Journal of Experimental Medicine Central Il-6Immune RegulationImmunologyImmunologic MechanismImmunotherapy	1996	345
Forced Mitotic Entry of S-Phase Cells as a Therapeutic Strategy Induced by Inhibition of WEE1 Marieke Aarts, Rachel Sharpe, Isaac García-Murillas, Cancer Discovery Cell DeathCytoskeletonCell CycleCancer BiologyCellular Physiology	2012	320
Impaired neutrophil response and CD4+ T helper cell 1 development in interleukin 6-deficient mice infected with Candida albicans. Luigina Romani, Antonella Mencacci, Elio Cenci, The Journal of Experimental Medicine Interleukin 6-Deficient MiceAdaptive Immune SystemInnate Immune SystemImmunologyImmune Regulation	1996	317
Discovery of 2-{4-[(3<i>S</i>)-Piperidin-3-yl]phenyl}-2<i>H</i>-indazole-7-carboxamide (MK-4827): A Novel Oral Poly(ADP-ribose)polymerase (PARP) Inhibitor Efficacious in BRCA-1 and -2 Mutant Tumors Philip Jones, Sergio Altamura, Julia K. Boueres, Journal of Medicinal Chemistry	2009	305
Androgen receptor inhibitor–induced “BRCAness” and PARP inhibition are synthetically lethal for castration-resistant prostate cancer Likun Li, Styliani Karanika, Guang Yang, Science Signaling	2017	293
Dual control of C-reactive protein gene expression by interleukin-1 and interleukin-6. Ursula Ganter, Rosaria Arcone, Carlo Toniatti, The EMBO Journal InflammationCytokineImmune RegulationImmunologyChronic Inflammation	1989	271

Page 1